BioCardia, Inc. (BCDA)

2.9700 -0.0100 (-0.34%) 收市：04:00PM EDT

BioCardia, Inc.

320 Soquel Way
Sunnyvale, CA 94085
United States
650 226 0120
https://www.biocardia.com

版塊: Healthcare
行業: Biotechnology
全職員工: 16

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Peter A. Altman Ph.D.	CEO, President & Director	515.51k	無	1967
Mr. David McClung	Chief Financial Officer	370.86k	無	1963
Mr. Edward M. Gillis	Senior Vice President of Devices	263.1k	無	1962

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. BioCardia, Inc. is based in Sunnyvale, California.

公司管治

截至 無 止，BioCardia, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。